Multimodality approaches to control esophageal cancer: development of chemoradiotherapy, chemotherapy, and immunotherapy.

Abstract

Esophageal cancer has a poor prognosis despite the fact that surgical techniques have been advanced and optimized, and systemic multimodality approaches have progressed recently. Adding chemotherapy, radiotherapy, and immunotherapy to the basic surgical approach have been shown to have therapeutic benefit for esophageal cancer. This review describes the latest development of chemoradiotherapy, chemotherapy, and immunotherapy, which have contributed to the reduction in esophageal cancer growth and improved the survival of patients. Chemoradiation is a treatment option for resectable esophageal cancer to preserve the esophagus for patients who cannot tolerate surgery. Moreover, a combination of chemoradiotherapy and salvage surgery could extend the survival of patients. The effects of a triplet chemotherapy regimen are currently being verified in some Phase III studies for unresectable advanced/recurrent esophageal cancer. In addition, with the great promise of immune checkpoint inhibitors, strategies that incorporate the use of immunotherapy may shift from the metastatic setting to the neoadjuvant/adjuvant setting as a result of clinical trials. More precise comprehension of the molecular biology of esophageal cancer is expected to further control disease progression using multimodality treatments in the future.

• Authors: Yoshihiro Kakeji, Taro Oshikiri, Gosuke Takiguchi, Shingo Kanaji, Takeru Matsuda, Tetsu Nakamura, Satoshi Suzuki
• Journal: Esophagus : official journal of the Japan Esophageal Society (Esophagus) Vol. 18 Issue 1 Pg. 25-32 (01 2021) ISSN: 1612-9067 [Electronic] Japan
• PMID: 32964312 (Publication Type: Journal Article, Review)

Topics

• Chemoradiotherapy
• Esophageal Neoplasms (pathology)
• Humans
• Immunotherapy
• Neoadjuvant Therapy
• Neoplasm Recurrence, Local (drug therapy, prevention & control)